|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 600 Massachusetts Ave, NW |
Address2 | SUITE 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Raymond Gill |
Date | 1/20/2022 6:10:55 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R.6201 - Families First Coronavirus Response Act, 2020
S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020
S.Con.Res 14- FY2022 Budget Resolution
H.R. 1319 - American Rescue Plan Act, 2021
H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act
-Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
-Strategic National Stockpile (SNS) Funding and Oversight
-Funding for FDA e-labeling rule implementation
-Patient access to Part B medicines during the COVID-19 public health emergency
-Issues related to 340B program oversight
-Support for increased investments to address antimicrobial resistance.
-Deficit reduction, reconciliation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Catherine |
Phillips |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Thomas |
Stoll |
|
|
|
Ravi |
Upadhyay |
|
|
|
Jill |
Shotzberger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S.1435 - Affordable Prescriptions for Patients Act of 2021
H.R. 2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R. 2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
S. 2774 - Pride in Patent Ownership Act
S. 2773 - Unleashing American Innovators Act
S. 2891 - Restoring the America Invents Act
H.R. 2891 - Preserve Access to Affordable Generics and Biosimilars Act
-Intellectual property and process patent issues
-Patent litigation reform
-PTAB and IPR processes
-Section 101 Reform
-Domestic and international compulsory licensing issues
-March-in Rights
-Product hopping
-Orange and purple book disclosures
-Hatch Waxman litigation
-Trade secret protections
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R.6201 - Families First Coronavirus Response Act, 2020
S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R.19, Lower Costs, More Cures Act of 2021
S.2164 - Lower Costs, More Cures Act (LCMCA)
H.R. 2113 - The Prescription Drug STAR Act
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
S.1895, Lower Health Care Costs Act of 2019
S. 4199, Prescription Drug Pricing Reduction Act of 2020
S.551 - REFUND Act of 2019
S.1712/H.R.4100 - DISARM Act of 2019
H.R.133 - Consolidated Appropriations Act, 2021
H.R. 6800 - The Heroes Act
H.R. 1319, American Rescue Plan Act of 2021
H.R. 2163/S. 464 - Safe Step Act
S.4796, The Fair Care Act of 2020
S.2076/H.R. 3932 PASTEUR Act
S.1773 - Prescription Drug Pricing Dashboard Act
S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program
S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies
H.R.5260 - Reduced Costs and Continued Cures Act
H.R. 5376 - Build Back Better Act
H.R. 3684- Infrastructure Investment and Jobs Act
H.R. 5030/S. 2706 - DIVERSE Trials Act
H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act
-Issues related to the 340B Drug Discount Program
-Issues relating to drug pricing
-Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives.
-Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars.
-General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
-Issues related to healthcare legislation
-Patient access to Part B medicines during the COVID-19 public health emergency
-Issues related to health equity, diversity, and inclusion in clinical trials
-Issues related to advanced development and procurement of medical countermeasures (MCMs)
-Issues related to patient assistance and access
-Issues relating to privacy and securing the data of and personal information of consumers
-Issues relating to medical research data
-Issues relating to screening and diagnostics
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Ravi |
Upadhyay |
|
|
|
Dan |
Neves |
|
|
|
Jill |
Shotzberger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R.19, Lower Costs, More Cures Act of 2021
S.2164 - Lower Costs, More Cures Act (LCMCA)
S.551, REFUND Act of 2019
H.R. 1499, the Protecting Consumer Access to Generic Drugs Act
S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act
H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act
H.R. 1319, The American Rescue Plan of 2021
S. 920 - The Affordable and Safe Prescription Drug Importation Act
S. 909 - The Prescription Drug Price Relief Act
S. 908 - The Medicare Drug Price Negotiation Act
S.4796, The Fair Care Act of 2020
S. 2428- False Claims Amendments Act of 2021
S.1773 - Prescription Drug Pricing Dashboard Act
H.R.5260 - Reduced Costs and Continued Cures Act
H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act
H.R. 5376 - Build Back Better Act
-Issues related to Medicare and Medicaid coverage and reimbursement
-Issues related to the 340B Drug Discount Program
-Issues related to drug pricing
-Medicare reimbursement for biosimilars
-MACRA treatment and reimbursement of Part B drugs
-Medicare payments for inpatient antimicrobials
-Issues related to drug importation
-Issues related to the International Pricing Index for Medicare Part B and general reference pricing
-Issues related to CMMI
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Jill |
Shotzberger |
|
|
|
Ravi |
Upadhyay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 1304, the American Innovation and R&D Competitiveness Act and
-Issues related to R&D tax deductions and expense amortization
-Issues related to supply chain incentives
-Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Catherine |
Phillips |
|
|
|
Matthew |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3788, the Protecting American Innovation Act
-Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver
-Issues related to compulsory licensing of foriegn patents
-Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
S. 3548 - CARES Act (Coronavirus Stimulus 3)
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R.6201 - Families First Coronavirus Response Act
H.R.133 - Consolidated Appropriations Act, 2021
S.2076/H.R. 3932 PASTEUR Act
-Issues related to public health protection including influenza development and preparedness
-Issues related to antimicrobial and antiviral research and product development
-Issues related to novel coronavirus and COVID-19 research and product development
-Issues related to drug development including PDUFA and Cures 2.0
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Gannon |
|
|
|
Elise |
Conner |
|
|
|
David |
Burt |
|
|
|
Catherine |
Phillips |
|
|
|
Dan |
Neves |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S.2543: Prescription Drug Pricing Reduction Act of 2019.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R.19, Lower Costs, More Cures Act of 2021
S.2164 - Lower Costs, More Cures Act (LCMCA)
S.551, REFUND Act of 2019
S.4796, The Fair Care Act of 2020
H.R.5260 - Reduced Costs and Continued Cures Act
-Drug pricing issues
-Prescription Drug User Fee Act reauthorization
-Issues related to prescription drug value
-Issues related to the 340B Drug Discount Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Ravi |
Upadhyay |
|
|
|
Jill |
Shotzberger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
none
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catherine |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
S.2782 - National Defense Authorization Act for Fiscal Year 2022
H.R.4350 - National Defense Authorization Act for Fiscal Year 2022
-Issues related to pharmaceutical supply chains and related security issues
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Matthew |
Sulkala |
|
|
|
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Ravi |
Upadhyay |
|
|
|
Dan |
Neves |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
Biden Administration EO 14001 A Sustainable Public Health Supply Chain
Biden Administration EO 14005 Ensuring the Future Is Made in All of America by All of America's Workers
Biden Administration EO 14017 Americas Supply Chains
-Issues related to pharmaceutical supply chains
-Issues related to reporting on location of origin of pharmaceutical products
-Issues related to drug shortages
-Issues related to pharmaceutical manufacturing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Stoll |
|
|
|
Dan |
Neves |
|
|
|
Jill |
Shotzberger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
H. R. 1177, The U.S. Citizenship Act
H.R. 3648, The Equal Access to Green cards for Legal Employment (EAGLE) Act of 2021
-Issues relating to limits and restrictions on the immigration of high skilled workers
-Issues relating to the immigration of medical researchers
17. House(s) of Congress and Federal agencies Check if None
Homeland Security - Dept of (DHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
FIN |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |